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CCHF in which the patient died of complications following 
surgical intervention for cerebral hemorrhage (8).
Death from CCHF usually occurs after 5–14 days of 
illness (1,8,9). The basic pathogenesis of CCHF virus at 
the molecular level is complex and not well defined. En-
dothelial cells, immune response, virus load, and coagula-
tion cascade play major roles in the disease pathogenesis. 
Blood and endothelium appear to be the target tissues of 
the disease (9). The coagulation cascade becomes activated 
over 24–48 hours; however, thrombin becomes activated 
and promotes edema formation and further disruption of 
the integrity of the blood–brain barrier. The edema forma-
tion starts when erythrocytes in the hematoma begin to lyse 
and its degradation products are deposited into the brain 
parenchyma, initiating a potent inflammatory reaction (10).
Although surgery remains the first choice for the treat-
ment of acute subdural hematoma, some patients may ben-
efit from conservative management with careful monitor-
ing. This report highlights the value of an early diagnosis 
of CCHF and neuroimaging for severe cases when brain 
hemorrhage is suspected.
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To the Editor: The central nervous system (CNS) 
manifestations of severe fever with thrombocytopenia syn-
drome (SFTS) include apathy, seizure, muscular tremor, 
and coma (1,2); however, the mechanism underlying CNS 
manifestations in SFTS is not clear. Deng et al. reported 
that illness of 15 (13%) of 115 patients with SFTS met the 
case definition for suspected encephalitis (1). However, 
they did not present any straightforward evidence of CNS 
invasion by STFS virus (SFTSV). Cui et al. similarly re-
ported that encephalitis developed in one fifth of 538 pa-
tients with SFTS (2). They found evidence of SFTSV by 
isolating the virus from the cerebrospinal fluid (CSF) in 1 
of 2 patients with SFTS whose CSF was obtained, but they 
did not mention CSF pleocytosis (2). We report a case of 
SFTS-associated encephalopathy, without pleocytosis and 
with normal CSF protein and glucose levels, that was con-
firmed by real-time reverse transcription PCR of the CSF. 
The patient was treated with experimental plasma exchange 
followed by convalescent plasma therapy.
During 2015, a 62-year-old woman who had a history 
of treated tuberculous meningitis 10 years earlier was ad-
mitted to a tertiary hospital in Seoul, South Korea (Republic 
of Korea), with a 5-day fever, myalgia, and headache. On 
hospital day (HD) 2, CSF examination revealed 1 leukocyte/
mm3, protein 35 mg/dL (reference 9–58 mg/dL), glucose 74 
mg/dL (reference 45–80 mg/dL), and CSF/blood glucose 
ratio 0.66 (reference 0.50–0.80). No bacteria or fungi were 
isolated from CSF. On HD 4, her headache worsened, and 
she displayed confused verbal responses and lacked orienta-
tion of time and place. No focal neurologic signs were ob-
served. On HD 5, magnetic resonance imaging of the brain 
indicated no additional abnormalities of the parenchyma 
and extra-axial structures except for a focal parenchymal 
defect in the right midbrain that had been discovered as a 
1306 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 7, July  2016
LETTERS
1These authors contributed equally to this article.
sequelae of tuberculous meningitis 10 years earlier. On HD 
7, follow-up CSF examination revealed no leukocytes, pro-
tein 57 mg/dL, glucose 209 mg/dL, and CSF/blood glucose 
ratio 0.62. SFTSV was detected by real-time reverse tran-
scription PCR (online Technical Appendix, http://wwwnc.
cdc.gov/EID/article/22/7/15-1791-Techapp1.pdf) in plasma 
and CSF (Figure). On HD 8, the patient became comatose 
and had no eye, verbal, and motor responses to noxious stim-
uli (Glasgow coma scale 3). Bilateral exotropia was noted 
with spared light and corneal reflexes and oculocephalic 
responses. Experimental plasma exchange was performed, 
and her viral load declined slightly; however, conscious-
ness and platelet count did not change. An ABO-identical 
nurse who had recovered from SFTS in September 2014 
agreed to donate plasma; her indirect immunofluorescence 
antibody assay (IFA) for SFTSV IgG had been 1:1,024 in 
October 2014. On HD 17, the patient’s titer of SFTSV IgG 
was 1:64 before the plasma therapy. We obtained ≈400 mL 
of convalescent plasma (IFA assay for SFTSV IgG 1:256 at 
the time of donation) from the donor and transfused it into 
the patient on HD 17. The viral load in the blood decreased 
steeply by a factor of 10 (6 × 102 to 6 × 101 copies/mL) dur-
ing the first 7 hours (4–11 pm on HD 17); it then gradually 
decreased from 3 × 101 at 7 am on HD 18 to 6 × 100 copies/
mL on HD 20, by which time the patient’s mental status had 
fully recovered (Figure).
This case is unique in that SFTS was detected in CSF 
in the absence of pleocytosis and with normal CSF pro-
tein and glucose levels, as in previous reports on influenza-
associated acute encephalopathy (3). Although headache 
and encephalitis can occur in patients with SFTS (1,2), 
the pathophysiology of CNS manifestations in SFTS is 
unknown. As with influenza-associated acute encepha-
lopathy, a possible hypothesis is direct invasion of SFTSV 
into the CNS; another hypothesis is that elevated cytokine 
levels or renal and hepatic dysfunction are associated with 
SFTS encephalopathy.
We are aware of 1 report of a favorable outcome of 
plasma exchange and ribavirin in 2 patients with SFTS and 
multiorgan failure in South Korea (4). However, the pa-
tients’ clinical condition did not substantially improve de-
spite the 5-day plasma exchange therapy and viral load only 
slightly decreased. Use of convalescent plasma therapy in 
severe acute respiratory syndrome, influenza A(H1N1) and 
A(H5N1), and Ebola virus disease has been reported (5–7), 
but little evidence exists to support its use. However, given 
the lack of conclusive data, these potential experimental 
treatments for emerging infectious diseases warrant further 
study in a clinical trial. Response was favorable in a mouse 
model of SFTS treated postexposure with antiserum from a 
patient who had recovered from SFTS (8). 
We do not know whether the convalescent plasma 
therapy given to the patient described here actually had a 
positive effect because her IFA titer was already increas-
ing around the time she received the plasma therapy. At the 
time of this writing, 2 patients with SFTS who were treated 
with intravenous immunoglobulin and corticosteroid had 
been reported (9). Cautious interpretation of these experi-
mental therapies is necessary because these therapies may 
not have had anything to do with the patients’ recovery.
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Figure. Changes in viral RNA load and immunofluorescence 
antibody titer and timing of therapies for a 62-year-old woman 
with SFTSV-associated encephalopathy in response to plasma 
exchange followed by convalescent plasma therapy, South Korea, 
2015. CSF, cerebrospinal fluid; IFA, indirect immunofluorescence 
antibody assay; SFTSV, severe fever with thrombocytopenia 
syndrome virus.
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To the Editor: Hepatitis A (HAV; family Picorna-
viridae; genus Hepatovirus) is an ≈7.5-kb single-stranded 
positive-sense RNA virus that causes acute inflammation 
of the liver in humans and nonhuman primates. Although 
HAV is most commonly transmitted by food and water 
contaminated with feces, humans have acquired HAV from 
handling infected nonhuman primates in captivity (1). 
HAV has been detected in recently imported captive 
primates after spontaneous outbreaks of acute hepatitis in 
animal facilities, but the definitive hosts of this virus have 
remained obscure (2,3). We identified by next-generation 
sequencing HAV in the blood of a free-living olive baboon 
(Papio anubis) from Kibale National Park, Uganda, sam-
pled in September 2010. Subsequent testing of a separate 
Kibale olive baboon troop in 2014 indicated the virus was 
prevalent and shed in feces.
As part of a long-term study of nonhuman primate 
health and ecology, 23 animals were immobilized and sam-
pled in 2010 as previously described (4). All animal pro-
tocols received prior approval from the Uganda National 
Council for Science and Technology (Kampala, Uganda), 
the Uganda Wildlife Authority (Kampala, Uganda), and the 
University of Wisconsin–Madison Animal Care and Use 
Committee (Madison, WI, USA). All samples were shipped 
in accordance with international laws under Convention on 
International Trade in Endangered Species of Wild Fauna 
and Flora Ugandan permit no. 002290.
During May 2012, we subjected total RNA from 1 mL 
of blood plasma of each animal to next-generation sequenc-
ing as previously described (4); results showed HAV-like 
sequences in 1 of 23 baboons. De novo assembly of these 
reads yielded a nearly complete HAV genome, which we 
term KibOB-1. KibOB-1 is most similar (94.2% nt iden-
tity; Figure) to AGM-27, an HAV originally detected in an 
African green monkey (Chlorocebus aethiops) imported to 
a Russian primate facility from Kenya (3).
For 11 baboons, we also collected a paired fecal sam-
ple, which we analyzed for evidence of viral shedding. 
Samples were preserved in RNAlater (Ambion Inc., Aus-
tin, TX, USA) at –20°C, and viral RNA was isolated by us-
ing the ZR Soil/Fecal RNA Microprep kit (Zymo Research, 
Irvine, CA, USA) following manufacturer’s protocols. 
Reverse transcription PCR (RT-PCR) of RNA was primed 
with random hexamers by using the RNA to cDNA Ecodry 
Premix (Random Hexamers) (Clontech Laboratories, Inc., 
Mountain View, CA, USA), and diagnostic PCR was con-
ducted with primers flanking the C-terminal extension of 
the HAV viral protein (VP) 1 gene (pX) by using the High 
Fidelity PCR Master Mix-Ecodry Premix (Clontech Labo-
ratories, Inc.). Five of 11 paired fecal samples tested posi-
tive for HAV by RT-PCR, indicating a higher prevalence of 
the virus in feces than in blood.
We then surveyed a second troop of habituated olive ba-
boons at the same field site during February–April 2014 (5). 
From these baboons, 7 of 19 fecal samples tested positive by 
RT-PCR. Confirmatory Sanger sequencing of RT-PCR am-
plicons was successful for 3 of these 7 animals (GenBank ac-
cession nos. KT819576–KT819578). Phylogenetic analyses 
of these sequences demonstrate monophyly and a low degree 
of interhost variability (>94% nt identity).
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